The Medical Patient’s Handbook (2026 Protocols)
The modern cannabis dispensary serves as a frontline health resource for millions. However, medical use in 2026 is governed by a "Titration" philosophy rather than "getting high."
The "Start Low, Go Slow" 2.0
For new medical patients, the 2026 protocol involves a Micro-dosing Diary.
Phase 1 (Days 1–3): Use only 1mg–2.5mg of CBD/THC before bed to assess initial sensitivity.
Phase 2 (Days 4–7): Introduce a daytime dose if the evening dose was well-tolerated.
Phase 3 (Weekly adjustment): Increase by 2.5mg increments until the "Therapeutic Window" is reached—the point where symptoms vanish without causing impairment.
Condition-Specific Recommendations
PTSD & Anxiety: In 2026, the focus has shifted toward high-CBD/low-THC ratios (such as 20:1) combined with the terpene Limonene. This provides the "anxiolytic" (anti-anxiety) benefit without the risk of THC-induced paranoia.
Chronic Pain & Inflammation: Patients are encouraged to use a "Multi-Modal" approach: an edible for long-term systemic relief, a topical for localized joint pain, and a vaporizer for "breakthrough" pain spikes.
Cancer & Chemotherapy: The "RSO" (Rick Simpson Oil) method remains a staple at the cannabis dispensary for those undergoing intense treatment, offering high-potency relief for nausea and appetite loss.